Teladoc and LifeMD have partnered with Gifthealth, Eli Lilly's pharmacy partner, to provide access to the weight-loss drug Zepbound, currently available through LillyDirect.

Eli Lilly is selling Zepbound directly to consumers via its LillyDirect platform, offering significant discounts but requiring out-of-pocket payments as most health insurers do not cover the drug, exacerbating affordability issues for many potential users.

Novo Nordisk is reducing the price of its weight loss drug Wegovy through a new direct-to-consumer pharmacy called NovoCare, making it more accessible for patients without insurance.

Novo Nordisk has reduced the price of Wegovy to $499 per month for patients without insurance coverage, aiming to improve accessibility after the end of the semaglutide shortage indicated by the FDA. The move mirrors similar initiatives by Eli Lilly. Experts suggest the price is still high, maintaining pressure on Novo Nordisk regarding drug affordability.

Eli Lilly announced a plan to invest at least $27 billion in new U.S. manufacturing sites to meet the rising demand for its weight loss and diabetes drugs, amidst a backdrop of reshoring manufacturing and enhancing supply chains.